Loxo Oncology

Loxo Oncology, Inc. is a biopharmaceutical company focused on developing targeted therapies for patients with genetically defined cancers in the United States. Founded in 2013 and headquartered in Stamford, Connecticut, the company is dedicated to rapidly advancing cancer treatments that demonstrate significant clinical potential. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) currently undergoing various clinical trials for multiple tumor types, including lung, head and neck, melanoma, colorectal, sarcoma, and breast cancers. In addition to larotrectinib, Loxo Oncology is advancing preclinical programs, including LOXO-195, a candidate addressing resistance mechanisms, as well as inhibitors targeting RET fusion proteins and FGFR isoforms. The company collaborates with several partners, including Array BioPharma and Illumina, to enhance its drug discovery and development processes. Loxo Oncology aims to leverage insights from diagnostic advancements to identify actionable targets and develop innovative treatments tailored to patients with specific genetic vulnerabilities.